Search

Displaying results 1 - 10 of 10000 in total
  1. Drug

    Armodafinil

    go.drugbank.com/drugs/DB06413
    ApprovedInvestigational

    Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. … Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S.

    Categories: armodafinil, Cytochrome P-450 CYP1A2 InducersSynonyms: Armodafinil, Armodafinilo
  2. Indication

    Shift-work related sleep disturbance

    go.drugbank.com/conditions/DBCOND0025087
    Drugs: Armodafinil · Modafinil
  3. Indication

    Somnolence

    go.drugbank.com/conditions/DBCOND0017811
    Drugs: Armodafinil · Caffeine
  4. Drug

    Arbutamine

    go.drugbank.com/drugs/DB01102
    Approved

    Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in

    Categories: Adrenergic beta-1 Receptor Agonists, Adrenergic beta-2 Receptor Agonists
  5. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in … It is a re-engineered version of the ultra long-acting oral basal insulin OI338, with several modifications introduced to significantly extend the half-life.

  6. Drug

    Testosterone propionate

    go.drugbank.com/drugs/DB01420
    ApprovedInvestigationalVet approvedWithdrawn

    Testosterone propionate is a slower-releasing anabolic steroid with a short half-life. … [T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  7. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.

    Products: CABLIVI®, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET
  8. Drug

    Conjugated estrogens

    go.drugbank.com/drugs/DB00286
    ApprovedInvestigational

    Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble. … sulfate, 3% of equilenin sulfate, 5% of 17-alpha and 17-beta-dihydroequilenin sulfate, 2% of 17-alpha-estradiolsulfate and 3% of 17-beta-estradiolsulfate.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: TROMODIL-V, PREMARIN CREMA V
  9. Indication

    Narcolepsy

    go.drugbank.com/conditions/DBCOND0017525
    Drugs: Amphetamine · Armodafinil · Dextroamphetamine · Ephedrine · Metamfetamine · Methylphenidate +5 more
  10. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.

    Categories: Vascular Endothelial Growth Factor A